PM360

SEPTEMBER 21, 2023

They do not have biosimilar or generic competition available in the market. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list. After this period, CMS will begin to include physician-administered drugs covered under Part B in the program.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. exclusions exist for orphan drug designation and biosimilar competition ).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

AUGUST 27, 2024

In our September 2023 report on the electrophysiology market, Clarivate projected that by 2028, PFA would represent 50% of the U.S. Increased appeal for dual-energy systems: Sometimes a situation calls for RF, but physicians like the ease and efficiency of PFA. ablation market and would have a total global market value of $3 billion.

Marketing 52

Marketing Competition FDA Electronics 52

Clarivate

APRIL 18, 2024

Humana is following a similar growth strategy as it sharpens competition with UnitedHealthcare in the Medicare Advantage sector. In 2019, UnitedHealth Group CEO David Wichmann indicated a plan to make Optum a $100B business by 2028, including by partnering with health systems for administrative services such as RCM and IT.

Retail 52

Retail Healthcare Healthcare Physicians 52

Clarivate

AUGUST 20, 2024

In 2026, CMS will select up to 15 additional Part B or Part D drugs for negotiations that take effect in 2028, and up to 20 additional drugs every year thereafter (Part B covers physician-administered drugs, including infusions of complex biologics).

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52